ArticleJournal of developmental and physical disabilities2018
Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD.
Article in Journal of developmental and physical disabilities, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Presence of recombination hotspots throughout SLC6A3.PloS one · 2019Trial
- Validating the Brief Autism Mealtime Behavior Inventory (BAMBI) in Persian and Kurdish for Use in Iran and the Kurdistan Region of Iraq.Journal of autism and developmental disorders · 2026Article
- The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health.International journal of molecular sciences · 2025Article
- Interaction between childhood trauma experience and TPH2 rs7305115 gene polymorphism in brain gray matter volume.Behavioral and brain functions : BBF · 2023Article
- Association between 19-bp Insertion/Deletion Polymorphism of Dopamine β-Hydroxylase and Autism Spectrum Disorder in Thai Patients.Medicina (Kaunas, Lithuania) · 2022Article
- Functional SLC6A3 polymorphisms differentially affect autism spectrum disorder severity: a study on Indian subjects.Metabolic brain disease · 2022Article
- Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder.Frontiers in neuroscience · 2022Review
- An Update on Precision Medicine Advances In Neurodevelopmental Disorders.Psychiatric annals · 2021Article
- Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder.Frontiers in genetics · 2020Article
- Validation of the Brief Autism Mealtime Behavior Inventory (BAMBI) Questionnaire.Journal of autism and developmental disorders · 2019Article
- Correlation between Neurotransmitter Transporter Gene Variants and Childhood Autism Spectrum Disorder: A Case-control Study.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundFrequent non-pathogenic genetic variants may act as moderators of phenotypic severity for complex disorders such as autism spectrum disorder (ASD). We previously identified polymorphisms affecting mRNA expression of candidate genes, including tryptophan hydroxylase 2 (
methodWe compare genotypes and (1) clinical response to atomoxetine, (2) scores from the Autism Diagnostic Interview-Revised (ADI-R), and (3) severity of Attention Deficit Hyperactivity Disorder (ADHD) symptoms in a cohort of patients with ASD from multiple study sites.
resultsThere was no association between CYP2D6 metabolizer status and atomoxetine response.
conclusionsWe find associations between ASD phenotypes and regulatory variants in catecholamine biosynthesis genes. This work may help guide future genetics studies related to ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.